Scinai Immunotherapeutics (SCNI) Short term Debt (2019 - 2026)

Scinai Immunotherapeutics (SCNI) posted Short term Debt of $354000.0 for Q1 2026, up 7.6% sequentially from $329000.0 in Q4 2025.

Scinai Immunotherapeutics (SCNI) Short term Debt (2019 - 2026) Analysis & Trends

Scinai Immunotherapeutics has reported Short term Debt for 8 years, with the latest figure at $354000.0 in Q1 2026.

Quarterly Short term Debt changed N/A year-over-year to $354000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $354000.0 (changed N/A YoY) and the FY2025 annual result came in at $329000.0, down 22.41% from the prior year.
Short term Debt grew to $354000.0 in Q1 2026 per SCNI's latest filing, from $329000.0 in the prior quarter.
Over five years, Short term Debt peaked at $1.8 million in Q1 2022 and troughed at $329000.0 in Q4 2025.
A 5-year average of $637214.3 and a median of $390500.0 in 2023 frame the typical range for Short term Debt.
The sharpest annual moves came in 2022 and 2025: Short term Debt slumped 99.97% in 2022, then surged 36.54% in 2025.
Over 5 years, Short term Debt stood at $382000.0 in 2022, then increased by 3.66% to $396000.0 in 2023, then increased by 7.07% to $424000.0 in 2024, then slipped by 22.41% to $329000.0 in 2025, then increased by 7.6% to $354000.0 in 2026.
According to Business Quant data, Short term Debt over the past three periods registered $354000.0, $329000.0, and $497000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Scinai Immunotherapeutics	11.72 Mn	-3.10 Bn	-1.12 Mn

Download Data